See more : Quixant Plc (QXT.L) Income Statement Analysis – Financial Results
Complete financial analysis of Reviva Pharmaceuticals Holdings, Inc. (RVPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Reviva Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Park-Ohio Holdings Corp. (PKOH) Income Statement Analysis – Financial Results
- Inui Global Logistics Co., Ltd. (9308.T) Income Statement Analysis – Financial Results
- Better World Acquisition Corp. (BWACW) Income Statement Analysis – Financial Results
- Bank of Xi’an Co.,Ltd. (600928.SS) Income Statement Analysis – Financial Results
- JF Technology Berhad (0146.KL) Income Statement Analysis – Financial Results
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
About Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 724.74K | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -724.74K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31,419.82B | 18.95M | 4.85M | 295.15K | 195.74K | 946.30K |
| General & Administrative | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8,083.82B | 5.36M | 5.25M | 2.14M | 181.12K | 175.58K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 39,503.64B | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Cost & Expenses | 39.50M | 24.31M | 10.10M | 2.43M | 376.86K | 1.12M |
| Interest Income | 0.00 | 182.80K | 0.00 | 105.18K | 201.00 | 0.00 |
| Interest Expense | 0.00 | 182.80K | 2.41K | 1.45M | 469.37K | 0.00 |
| Depreciation & Amortization | 0.00 | 194.71K | 236.56K | 105.77K | 846.00 | 1.02K |
| EBITDA | -39,503.64B | -24.11M | -10.10M | -2.33M | -376.01K | -1.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39,503.64B | -24.31M | -10.10M | -2.43M | -376.86K | -1.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 39,503.60B | -11.91K | 1.59M | -1.35M | -469.17K | -557.68K |
| Income Before Tax | -39.24M | -24.32M | -8.52M | -3.78M | -846.03K | -1.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -16.95B | 20.78K | 6.00K | 800.00 | 800.00 | 800.00 |
| Net Income | -39,260.84B | -24.34M | -8.52M | -3.78M | -846.83K | -1.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| EPS Diluted | -1.65 | -1.25 | -0.58 | -1.24 | -0.31 | 0.00 |
| Weighted Avg Shares Out | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
| Weighted Avg Shares Out (Dil) | 23.80M | 19.52M | 14.79M | 3.06M | 2.77M | 0.00 |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPH
RVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPH
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
Reviva to Present at the UBS Virtual CNS Day
Reviva to Present at the 36th Annual ROTH Conference
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Source: https://incomestatements.info
Category: Stock Reports